Excelsior Biopharma (6496) — Capital Reinvestment Ratio
Excelsior Biopharma (6496) has a Capital Reinvestment Ratio of 3.80x as of June 2025, meaning it reinvests 4% of its operating cash flow (NT$3.80 Million) in capital expenditures (NT$14.44 Million). Check 6496 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Excelsior Biopharma Capital Reinvestment Ratio (2017–2022)
This chart tracks Excelsior Biopharma's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see 6496 cash generation efficiency.
Annual Capital Reinvestment Ratio for Excelsior Biopharma (2017–2022)
Year-by-year Capital Reinvestment Ratio for Excelsior Biopharma from 2017 to 2022. See 6496 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 1.42x | NT$5.49 Million | NT$7.78 Million | ▲ +2652.7% |
| 2021 | 0.05x | NT$55.82 Million | NT$2.88 Million | ▲ +131.1% |
| 2020 | 0.02x | NT$520.81 Million | NT$11.62 Million | ▼ -70.3% |
| 2018 | 0.08x | NT$126.92 Million | NT$9.54 Million | ▲ +45.2% |
| 2017 | 0.05x | NT$349.47 Million | NT$18.10 Million | — |